Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Zacks Research

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Monday, Zacks reports.

A number of other analysts have also weighed in on REGN. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Leerink Partners upped their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a report on Monday, August 17th. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Finally, Truist Financial boosted their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $802.18.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $750.51 on Monday. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock has a market cap of $77.27 billion, a PE ratio of 18.55, a P/E/G ratio of 1.47 and a beta of 0.20. The company has a 50-day moving average price of $782.91 and a 200 day moving average price of $720.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the prior year, the company posted $12.81 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,146 shares of company stock valued at $3,432,488 over the last three months. 6.97% of the stock is owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $5,682,636,000. State Street Corp boosted its holdings in Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after purchasing an additional 170,210 shares in the last quarter. Franklin Resources Inc. grew its stake in Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after buying an additional 106,861 shares during the last quarter. Nuveen LLC raised its position in Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Regeneron Pharmaceuticals by 7.2% in the fourth quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock valued at $1,228,127,000 after acquiring an additional 106,632 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sell-side analysts collectively rate Regeneron a “Moderate Buy,” indicating that the broader analyst consensus remains favorable. Regeneron also compares attractively on valuation against some biotechnology peers. Regeneron Pharmaceuticals Stock Rated Moderate Buy by Sell-Side Analysts
• Positive Sentiment: Biohaven has begun enrolling patients in a combination study pairing its investigational cancer therapy BHV-1530 with Regeneron’s Libtayo. The agreement could support additional development opportunities for Libtayo, though the program remains early stage. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is expected to report third-quarter results on October 30. The upcoming earnings release may provide updates on Eylea demand, guidance and the company’s broader pipeline, making it a near-term catalyst. Should You Buy Regeneron Pharmaceuticals Stock Before October 30?
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK results for two potential wet age-related macular degeneration treatments. The candidates met primary endpoints versus Eylea and may offer dosing approximately every six months, compared with Eylea’s current roughly eight-week schedule. The data raise the prospect of longer-term competitive pressure on Regeneron’s key eye-care franchise and prompted a sharp rally in Kodiak shares. Kodiak Skyrockets on Positive Study Data for Two Eye Drugs
• Negative Sentiment: Royal Bank of Canada reaffirmed its “Sector Perform” rating and set a $737 price target, below the referenced share price, signaling limited near-term upside in that analyst’s view. Regeneron Sector Perform Rating Reaffirmed by RBC

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.